CXCR4 and neoplasm: Consistent with CXCR4 role in the mobilization and survival of endothelial cell precursors, AMD3100, an antagonist of this receptor administered to HIV-infected individuals, effectively impairs tumor vasculogenesis in pre-clinical models (68, 111).